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Jo Rick10* , Peter Bower10, Sandra Eldridge11, Vichithranie W. Madurasinghe11 and Jonathan Graffy12Abstract
Background: Randomised controlled trials are generally regarded as the ‘gold standard’ experimental design to
determine the effectiveness of an intervention. Unfortunately, many trials either fail to recruit sufficient numbers of
participants, or recruitment takes longer than anticipated. The current embedded trial evaluates the effectiveness of
optimised patient information sheets on recruitment of participants in a falls prevention trial.
Methods: A three-arm, embedded randomised methodology trial was conducted within the National Institute for
Health Research-funded REducing Falls with ORthoses and a Multifaceted podiatry intervention (REFORM) cohort
randomised controlled trial. Routine National Health Service podiatry patients over the age of 65 were randomised
to receive either the control patient information sheet (PIS) for the host trial or one of two optimised versions, a
bespoke user-tested PIS or a template-developed PIS. The primary outcome was the proportion of patients in each
group who went on to be randomised to the host trial.
Results: Six thousand and nine hundred patients were randomised 1:1:1 into the embedded trial. A total of 193 (2.8%)
went on to be randomised into the main REFORM trial (control n= 62, template-developed n= 68; bespoke user-tested
n= 63). Information sheet allocation did not improve recruitment to the trial (odds ratios for the three pairwise
comparisons: template vs control 1.10 (95% CI 0.77–1.56, p= 0.60); user-tested vs control 1.01 (95% CI 0.71–1.45, p= 0.94);
and user-tested vs template 0.92 (95% CI 0.65–1.31, p= 0.65)).
Conclusions: This embedded methodology trial has demonstrated limited evidence as to the benefit of using optimised
information materials on recruitment and retention rates in the REFORM study.
Trial registration: International Standard Randomised Controlled Trials Number registry, ISRCTN68240461. Registered on 01
July 2011.
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Randomised controlled trials (RCTs) are generally
regarded as the ‘gold standard’ experimental design to
determine the effectiveness of an intervention. Unfortu-
nately, many trials either fail to recruit sufficient
numbers of participants, or recruitment takes longer
than anticipated [1]. Such difficulties not only have an
impact on the power and external validity of the study’s
findings but may also increase the overall financial cost.
Many trials implement methods to improve recruitment
and/or retention such as the use of monetary incentives.
There is, however, limited evidence as to the effective-
ness of recruitment strategies in healthcare settings [2],
and as a result, the UK Medical Research Council
funded the Systematic Techniques for Assisting Recruit-
ment to Trials (MRC START) research programme [3].
The aim of this programme was to “improve the
evidence-base of recruitment to trials, enhance recruit-
ment rates and make research more accessible to the
public.” One key objective of the project was to develop
interventions to improve recruitment to trials and test
them in embedded trials within ongoing ‘host’ trials. The
initial focus was on testing optimised patient informa-
tion sheets and multimedia resources.
Patient information sheets (PISs) are always given to
potential trial participants along with verbal information
as part of the informed consent process. A trial PIS has
to be reviewed and approved by an ethics committee or
an internal review body; nonetheless, there remain long-
standing concerns regarding their length, complexity
and the level of literacy skills required to understand the
information, all of which may have a negative impact on
recruitment [4]. Indeed, a recent sample of 20 PISs from
recently completed or ongoing RCTs were found to be
lengthy (mean word count 1853, standard deviation = 960)
and lacking information important to making an informed
decision about trial participation [5]. However, Brierley
et al. found that reducing the length of the PIS did not in-
fluence recruitment and actually yielded more ineligible
patients [6]. Therefore, simply producing a shorter PIS is
ineffective, and the content and interpretability of the
information presented must be retained. One possible ap-
proach to improve the quality and appearance of PISs is
to develop their content through a process of re-writing
(for a lay audience), re-organisation, enhancing their ap-
pearance through input from a graphic designer and in-
volving user testing [7, 8]. The use of a professionally
designed information pack was seen to have a small posi-
tive effect on initial response rates relative to a ‘standard’
pack (2.7% difference in response rates, 95% confidence
interval (CI) −0.06 to 5.5%, p = 0.06) in an RCT embedded
in an Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort [9]. However, undertaking commercial
user testing and incorporating graphic design input intoPISs is costly, especially if the process needs to be com-
pleted for each trial; therefore, it has been suggested that a
‘bank’ of template PISs could be developed (which have
been re-written and have undergone bespoke user testing
and graphic design) in different populations. Researchers
could select the most appropriate template on which to
base their trial PIS according to their particular study
population.
Embedding recruitment trials into ongoing trials is an
efficient method to test recruitment strategies, and to
help fill the knowledge gap with minimal resource use
[10]. Table 1 presents a Consolidated Standards of
Reporting Trials (CONSORT) checklist for reporting
embedded recruitment trials. The REFORM study team
were invited by the MRC START programme to embed
a recruitment methodology trial within the REducing
Falls with ORthoses and a Multifaceted podiatry inter-
vention (REFORM) study. The REFORM study was se-
lected, as the aims of the MRC START programme were
compatible with both the need to maximise recruitment
to the REFORM trial and the ethos of the York Trials Unit
(YTU) to develop an understanding of effective recruit-
ment interventions. The aim of the designed three-arm
embedded trial was to determine if the number of partici-
pants recruited, randomised and retained to the REFORM
trial could be improved by the use of both a bespoke user-
tested and a template-developed optimised PIS.
Methods
Ethics approval
This trial was embedded within the National Institute
for Health Research (NIHR)-funded REFORM study
[11], which aims to evaluate the clinical and cost effect-
iveness of a podiatry intervention for the prevention of
falls in older people. Ethical approval for the REFORM
study was given by NRES East of England – Cambridge
East Research Ethics Committee and the University of
York, Department of Health Sciences Research Governance
Committee. Ethical approval for the PIS embedded method-
ology trial was given via a substantial amendment to the
same committees. The embedded methodology trial is regis-
tered as a substudy to REFORM (ISRCTN68240461).
Participant recruitment
REFORM is a cohort RCT [12] in which patients were
initially recruited to an observational cohort before po-
tentially being randomised into an RCT. Electronic med-
ical notes at participating National Health Service (NHS)
podiatry clinics were searched to identify community-
dwelling patients eligible for the REFORM observational
cohort (i.e. those who were over the age of 65 and had
attended a routine podiatry appointment within the past
6 months). Potentially eligible participants were mailed
an invitation pack (letter of invitation, one of the three
Table 1 Checklist of items for reporting embedded recruitment trials
Section/topic and item no. CONSORT 2010 (standard) checklist item Extension for embedded recruitment trials
Title and abstract
1a Identification as a randomised trial in the title Identification as an embedded randomised recruitment
trial in the title
1b Structured summary of trial design, methods,
results and conclusions (for specific guidance
see CONSORT for abstracts)
Structured summary of embedded recruitment trial design,
methods, results and conclusions (for specific guidance
see CONSORT for abstracts)
Introduction
Background and objectives
2a Scientific background and explanation of rationale Scientific background and explanation of rationale for
embedded recruitment trial including a brief description
of the host trial(s) as appropriate
2b Specific objectives or hypotheses Specific objectives or hypotheses for embedded
recruitment trial
Methods
Trial design
3a Description of trial design (such as parallel, factorial)
including allocation ratio
Description of embedded recruitment trial design
(such as parallel, factorial, cluster) including
allocation ratio
3b Important changes to methods after trial
commencement (such as eligibility criteria),
with reasons
Important changes to methods of the embedded
recruitment trial after commencement (such as
eligibility criteria), with reasons
Participants
4a Eligibility criteria for participants Eligibility criteria for participants for embedded
recruitment trial, including any differences from
those for the host trial(s)
4b Settings and locations where the data were collected Settings and locations where the embedded
recruitment trial was carried out, including a
brief description of the host trial(s) as appropriate
Interventions
5 The interventions for each group with sufficient
details to allow replication, including how and
when they were actually administered
The interventions for each group (including
control group) within the embedded recruitment
trial with sufficient details to allow replication,
including how, where and when they were
actually administered
Outcomes
6a Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed
Completely defined pre-specified primary and
secondary outcome measures for the embedded
recruitment trial, including how and when they
were assessed
6b Any changes to trial outcomes after the trial
commenced, with reasons
Any changes to embedded recruitment trial
outcomes after the embedded recruitment trial
commenced, with reasons
Sample size
7a How sample size was determined How sample size for embedded recruitment
trial was determined
7b When applicable, explanation of any interim
analyses and stopping guidelines
When applicable, explanation of any interim
analyses and stopping guidelines for
embedded recruitment trial
Randomisation
Sequence generation
8a Method used to generate the random
allocation sequence
Method used to generate the random allocation
sequence for embedded recruitment trial
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Table 1 Checklist of items for reporting embedded recruitment trials (Continued)
8b Type of randomisation; details of any
restriction (such as blocking and block size)
Type of randomisation; details of any restriction
(such as blocking and block size) in embedded
recruitment trial
Allocation concealment mechanism
9 Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any steps
taken to conceal the sequence until
interventions were assigned
Mechanism used in the embedded recruitment trial
to implement the random allocation sequence
(such as sequentially numbered containers),
describing any steps taken to conceal the
sequence until interventions were assigned
Implementation
10 Who generated the random allocation
sequence, who enrolled participants and
who assigned participants to interventions
Who generated the random allocation sequence(s),
who enrolled participants and who assigned
participants to embedded recruitment interventions
Blinding
11a If done, who was blinded after assignment
to interventions (for example, participants,
care providers, those assessing outcomes)
and how
If done, who was blinded after assignment to
embedded recruitment interventions (for example,
participants, care providers, those assessing
outcomes) and how
11b If relevant, description of the similarity of
interventions
If relevant, description of the similarity of
interventions in the embedded recruitment trial
Statistical methods
12a Statistical methods used to compare groups
for primary and secondary outcomes
Statistical methods used to compare groups for
primary and secondary outcomes of the embedded
recruitment trial
12b Methods for additional analyses, such as
subgroup analyses and adjusted analyses
Methods for additional analyses, such as subgroup
analyses and adjusted analyses for embedded
recruitment trial
Results
Participant flow (a diagram is strongly recommended)
13a For each group, the numbers of participants
who were randomly assigned, received
intended treatment and were analysed for
the primary outcome
For each group in the embedded recruitment trial,
the numbers of participants who were randomly
assigned, received intended treatment and were
analysed for the primary outcome
13b For each group, losses and exclusions after
randomisation, together with reasons
For each group, losses and exclusions after
randomisation to embedded recruitment trial,
together with reasons
Recruitment
14a Dates defining the periods of recruitment
and follow-up
Dates defining the periods of recruitment and
follow-up for both embedded recruitment trial
and host trial(s)
14b Why the trial ended or was stopped Why the embedded recruitment trial ended or
was stopped
Baseline data
15 A table showing baseline demographic
and clinical characteristics for each group
If possible a table showing baseline characteristics
of each arm of the embedded recruitment trial
Numbers analysed
16 For each group, number of participants
(denominator) included in each analysis
and whether the analysis was by original
assigned groups
For each group in the embedded recruitment trial,
number of participants (denominator) included
in each analysis and whether the analysis was
by original assigned groups
Outcomes and estimation
17a For each primary and secondary outcome,
results for each group, and the estimated
effect size and its precision (such as 95%
confidence interval)
For each primary and secondary outcome, results
for each group in the embedded recruitment trial,
and the estimated effect size and its precision
(such as 95% confidence interval)
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Table 1 Checklist of items for reporting embedded recruitment trials (Continued)
17b For binary outcomes, presentation of both
absolute and relative effect sizes is
recommended
For binary outcomes in the embedded recruitment
trial, presentation of both absolute and relative
effect sizes is recommended
Ancillary analyses
18 Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing pre-specified
from exploratory
Results of any other analyses performed for embedded
recruitment trial, including subgroup analyses and
adjusted analyses, distinguishing pre-specified
from exploratory
Harms
19 All important harms or unintended effects
in each group (for specific guidance
see CONSORT for harms)
All important harms or unintended effects in each
group for both the embedded recruitment trial and
host trial(s) (for specific guidance see CONSORT
for harms)
Discussion
Limitations
20 Trial limitations, addressing sources of
potential bias, imprecision and, if relevant,
multiplicity of analyses
Embedded recruitment trial limitations, addressing
sources of potential bias, imprecision and, if relevant,
multiplicity of analyses
Generalisability
21 Generalisability (external validity, applicability)
of the trial findings
Generalisability (external validity, applicability) of
the embedded recruitment trial findings
Interpretation
22 Interpretation consistent with results,
balancing benefits and harms, and considering
other relevant evidence
Interpretation consistent with results of the
embedded recruitment trial, balancing benefits
and harms, and considering other relevant evidence
Other information
Registration
23 Registration number and name of trial registry Registration number and name of trial registry
(for all host trials and embedded recruitment trial
if available)
Protocol
24 Where the full trial protocol can be accessed,
if available
Where the embedded recruitment trial protocol can
be accessed, if available
Funding
25 Sources of funding and other support
(such as supply of drugs), role of funders
For embedded recruitment trial, sources of funding
and other support, role of funders and collaborators
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form, screening questionnaire and prepaid envelope)
asking whether they would like to participate in the RE-
FORM study. The information and consent process
covered all aspects of the cohort and trial, and so only
one PIS was seen by participants whether they went on
to be randomised into the REFORM trial or not. Partici-
pants who returned their completed consent and screen-
ing form to the YTU by post were assessed by
researchers at the YTU for eligibility. Participants were
ineligible if they reported neuropathy, dementia or an-
other neurological condition such as Parkinson’s or
Alzheimer’s disease; were unable to walk household dis-
tances without the help of a walking aid; or had a lower
limb amputation or were unwilling to attend their localpodiatry clinic. Eligible participants were sent a baseline
questionnaire and monthly falls calendars. Participants
who returned a baseline questionnaire and at least one
monthly falls calendar (recording falls in the previous
month) were included in the observational cohort.
Those cohort participants who had either had one fall in
the past 12 months or one fall in the past 24 months re-
quiring hospital attention, or who reported a fear of fall-
ing on the baseline questionnaire (worried about falling
at least some of the time in the past 4 weeks) were then
eligible for randomisation to the REFORM trial. During
the course of the trial, cohort participants who went on
to have a fall could then become eligible for the RE-
FORM trial. In order to minimise the delay between ran-
domisation and the podiatrist seeing the participants in
Cockayne et al. Trials  (2017) 18:144 Page 6 of 10clinic for their REFORM appointment, participants were
randomised when clinics had capacity and not at the
point of becoming eligible for the trial.
At the point at which this embedded trial was nested
within the host trial, the next podiatry clinics due to
begin recruitment were Harrogate, Leeds, Scarborough,
Selby and Sheffield. All patients due to be sent a RE-
FORM invitation pack from these clinics were rando-
mised to one of the three arms in the embedded
methodology trial which determined which format of
PIS they were sent.
Randomisation and blinding
This was an embedded, individually randomised, recruit-
ment trial. A list of patients was generated and ordered
by NHS number. Each patient was assigned a unique
identification number. An independent data manager at
the YTU, who was not involved in the recruitment of
participants, generated the allocation sequence for the
embedded methodology trial electronically. Randomisa-
tion was stratified by centre, using a single large block
per site, which corresponded to its total sample size.
Participants were allocated 1:1:1 to receive, in their invi-
tation pack, either (1) the control PIS and control invita-
tion letter; or (2) an optimised version of the PIS and
invitation letter developed through bespoke user testing;
or (3) an optimised template-developed PIS and the ori-
ginal invitation letter. Patients were then sent the allo-
cated invitation pack by members of the research team
based at the University of York. The researchers,
patients and podiatrists were blind to the allocation. Pa-
tients who received the information sheet were unaware
that they had been randomised to receive different infor-
mation leaflets.
Control group
The ‘control’ PIS was the original PIS developed for the
REFORM trial. It was written in accordance with the
standard National Research Ethics Service template
available at the time at which the study was set up. It
underwent several revisions by the research team and
was five pages of A4 paper in length. The invitation let-
ter was one A4 page on NHS trust headed paper. The
control PIS is shown in Additional file 1.
Intervention group: ‘bespoke user-tested’ PIS
The ‘bespoke user-tested’ PIS was developed in the
following way: it was re-written for a lay audience (led
by author PK), re-organised into eight subsections, had
graphic design input and underwent user testing. The
graphic design and user testing were both undertaken by
commercial companies. Staff members who had consid-
erable experience in writing patient material and a
graphic designer revised the content and layout of thecontrol PIS. A contents list was placed on the front page
along with a list of key points about the study, with the
main text divided into eight sections. Sentences and par-
agraphs were shortened and bullet points used for lists.
The PIS then underwent three rounds of user testing,
each involving 10 members of the public with limited
podiatry- or trial-specific knowledge. During the user-
testing process, the users (a group demographically simi-
lar to the REFORM trial target population but with no
history of falls) were asked to find key pieces of informa-
tion in the PIS relating to: the nature and purpose of the
trial; the process and meaning of consent; and trial pro-
cedures and safety issues. Questions were arranged in
such a way to ensure they did not match the order
within the PIS. The final version of the PIS was printed
on one sheet of double-sided A3 paper and folded to
form a booklet. The control one-page invitation letter was
revised and underwent user testing alongside the PIS, result-
ing in shortened text and the addition of bullet points to
clarify what to do if the participant wished to take part. The
user-tested PIS is shown in Additional file 2.Intervention group: ‘template-developed’ PIS
The ‘template-developed’ PIS was written by three research
fellows with more than 12 years’ experience of recruiting
patients to a range of randomised trials and who were cur-
rently working on the REFORM study. The content, layout
and style were revised using a previously bespoke user-
tested PIS designed for an earlier trial conducted in a similar
aged population [13]. In this process, the control PIS text
was shortened and divided into seven sections, a contents
list included and bullet points added to clarify what the par-
ticipant should do if he/she wished to take part. A green
colour scheme was used to match the trial logo. The PIS
was reviewed and revised further by two other experienced
researchers. The Public and Patient Involvement (PPI) group
reviewed this PIS and gave feedback about its readability,
layout, font size and content; however, no graphic design in-
put or formal user testing was undertaken. The revised ver-
sion was printed on one sheet of double-sided A3 paper and
folded to form a booklet. Participants in the template-
developed PIS group were sent the same patient invitation
letter as the control group. The template-developed PIS is
shown in Additional file 3.Primary outcome
The primary outcome was the proportion of patients in
each group who went on to be randomised into the
REFORM trial.Secondary outcomes
Secondary outcomes were as follows:
Fig. 1 Flow diagram to depict the flow of participants in the PIS
embedded methodology trial
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recruited into the REFORM cohort
 Proportion of patients retained in the trial at
3 months post randomisation defined as returning at
least the first 3 months’ worth of falls calendars
from the date of randomisation.
Sample size
As is usual with an embedded trial within a trial, no for-
mal power calculation was undertaken for this embed-
ded methodology trial, but the MRC START programme
set out to include trials which planned to approach
enough potential participants to allow 400 potential re-
cruits to receive each recruitment intervention. Five cen-
tres were involved in the substudy; thus, the sample was
constrained to only include participants eligible for the
REFORM study who were due to be mailed a recruit-
ment pack from these centres.
Statistical analysis
The proportion of participants who: returned a consent
form; were recruited into the cohort; were randomised
into the main trial; and were retained in the trial is pre-
sented for the three groups. Odds ratios (ORs) and 95%
confidence intervals (CIs) for each of the three pairwise
comparisons were obtained from mixed logistic regression
models adjusting for PIS allocation as a fixed effect and
trial centre as a random effect. Analysis was conducted in
Stata v13, using two-sided tests at the 5% significance level
and based on the principles of intention to treat.
To account for the participants in the embedded trial
of the newsletter who overlapped with participants in
this trial, sensitivity analyses were conducted including a
covariate for receiving a newsletter in all logistic
regressions.
Results
A total of 6900 recruitment packs were sent to potential
REFORM study participants across five centres between
March 2013 and May 2014: Harrogate (n = 500, 7.3%),
Scarborough (n = 1000, 14.5%), Selby (n = 1000, 14.5%),
Sheffield (n = 1600, 23.2%) and Leeds (n = 2800, 40.6%)
(Fig. 1). Potential participants were sent a recruitment
pack containing either the control version of the PIS
(n = 2298, 33.3%), the template-developed PIS (n =
2301, 33.4%) or the user-tested PIS (n = 2301, 33.4%).
Responses to invitation
A consent form and screening questionnaire were
returned by 755 or 10.9% of individuals (control n = 254
(11.1%); template-developed n = 246 (10.7%); user-tested
n = 255 (11.1%)). PIS allocation did not significantly im-
prove the response (chi-square 0.22, degrees of freedom
= 2, p = 0.89). No one group was more likely to respond(template-developed vs control OR 0.96, 95% CI 0.80–
1.16, p = 0.69; bespoke user-tested vs control OR 1.00,
95% CI 0.83–1.21, p = 0.98; and bespoke user-tested vs
template-developed OR 1.04, 95% CI 0.86–1.25, p = 0.67).
Randomised to REFORM trial
Eligible, consenting participants were then sent a base-
line questionnaire (control n = 145 (6.3%); template-
developed n = 158 (6.9%); bespoke user-tested n = 160
(7.0%)). A baseline form and at least one falls calendar
were returned by 134 (5.8%) individuals in the control
group, 149 (6.5%) in the template-developed group and
149 (6.5%) in the bespoke user-tested group. These
participants were recruited to the cohort of potentially
eligible participants.
Of these cohort patients, 161 were immediately eligible
for randomisation into REFORM, and of these, 122
could be randomised as there was sufficient capacity in
the clinics to see them. A further 71 patients in the
cohort became eligible for the trial as they subsequently
reported a fall and were able to be seen in clinic. There-
fore, a total of 193 of the 6900 potential participants
(2.8%) went on to be randomised into the main RE-
FORM trial (control n = 62 (2.7%, 95% CI 2.0–3.4%);
template-developed n = 68 (3.0%, 95% CI 2.3–3.6%);
Cockayne et al. Trials  (2017) 18:144 Page 8 of 10bespoke user-tested n = 63 (2.7%, 95% CI 2.1–3.4%)).
The difference in percentages and their 95% CIs are as
follows: for template-developed vs controls there was a
0.3 percentage point difference (95% CI −0.7 to 1.2, p =
0.60); bespoke user-tested vs control 0.0 (95% CI −0.9 to
1.0, p = 0.93); and bespoke user-tested vs template-
developed −0.2 (95% CI −1.2 to 0.7, p = 0.66).
Descriptive data for these participants are presented in
Table 2. PIS allocation did not improve recruitment to the
trial (chi-square 0.33, degrees of freedom = 2, p = 0.85).
The odds ratios for the three pairwise comparisons
were: template-developed vs control 1.10 (95% CI
0.77–1.56, p = 0.60); bespoke user-tested vs control
1.01 (95% CI 0.71–1.45, p = 0.94); and bespoke user-
tested vs template-developed 0.92 (95% CI 0.65–1.31,
p = 0.65).
Retention rates
In total, 162 participants were retained in the trial (con-
trol n = 56 (2.4%); template-developed n = 53 (2.3%);
user-tested n = 53 (2.3%)).
Sensitivity analyses
Three hundred and thirty four participants also received
a newsletter in their recruitment pack (control n = 120Table 2 Characteristics of participants randomised into the main tria
Characteristic Control (n = 62) Template-develo
Gender, n (%)
Male 24 (38.7) 32 (47.8)
Age
Mean (SD) 78.3 (5.8) 78.6 (6.6)
Fallen in previous 6 months? n (%)
Yes 23 (37.1) 29 (43.3)
No 39 (62.9) 36 (53.7)
Don’t know 0 (0.0) 2 (3.0)
If fallen in previous 6 months, how many times?
Median (min,max) 1 (1, 5) 1 (1, 20)
Worried about having a fall during the previous 4 weeks
All of the time 4 (6.5) 3 (4.5)
Most of the time 1 (1.6) 4 (6.0)
A good bit of the time 6 (9.7) 3 (4.5)
Some of the time 19 (30.7) 13 (19.4)
A little of the time 23 (37.1) 27 (40.3)
None of the time 9 (14.5) 17 (25.4)
Short Falls Efficacy Scale – International (FES-I)a
Mean (SD) 13.1 (5.0) 11.7 (4.3)
Frenchay Activities Index (FAI)a
Mean (SD) 47.2 (6.7) 46.5 (7.2)
aFES-I scored from 7–28, higher score indicates greater concern about the possibilit(5.2%); template-developed n = 112 (4.9%); bespoke user-
tested n = 102 (4.4%)). In the sensitivity analyses, only a
negligible difference in the estimates, their associated
95% CIs and p values was observed.
Discussion
We have evaluated the effectiveness of two optimised
patient information sheets (PISs) relative to the standard
control version developed using the NRES template PIS
to increase recruitment to the REFORM trial. Previous
studies investigating the method of delivering paper-
based information to patients have found that reducing
the length of the PIS or supplementing the PIS with a
booklet on clinical trials has little or no impact on trial
recruitment, but that the use of a professionally designed
information pack may be effective [6, 9, 14]. Alternative
strategies could be evaluated in future embedded trials.
Bower et al. [10] have identified three areas which merit
further investigation. These include training site staff,
communication with patients and incentives. The key
finding of this study is that the use of enhanced PISs did
not significantly increase recruitment or retention. The
overall recruitment rate to the REFORM trial (2.8%) and
the REFORM cohort (6.3%) was low, so it may be that
there was insufficient power to detect a difference. Thel by PIS allocation
ped (n = 68) Bespoke user-tested (n = 63) Total (n = 193)
27 (43.6) 83 (43.5)
77.5 (7.8) 78.1 (6.8)
27 (42.9) 79 (41.2)
36 (57.1) 111 (57.8)
0 (0.0) 2 (1.0)
1 (1, 6) 1 (1, 20)
4 (6.4) 11 (5.7)
2 (3.2) 7 (3.7)
4 (6.4) 13 (6.8)
9 (14.3) 41 (21.4)
29 (46.0) 79 (41.2)
15 (23.8) 41 (21.4)
12.1 (4.5) 12.3 (4.7)
46.4 (7.1) 46.6 (7.0)
y of falling; FAI scored from 15–60, higher score indicates greater activity
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which will have more power to provide evidence of ef-
fectiveness. Small differences in recruitment rates could
make a large difference to trials similar to REFORM,
which required a sample size of nearly 900 participants.
For example, a 3% uptake would require 30,000 invita-
tions, but if uptake to the study increased to 4%, then
7500 fewer recruitment packs would be required, saving
up to £35,000 in packing and postage costs alone. This
would be a significant saving, even after incorporating
the cost of professional graphic design and bespoke user
testing. In this study, there were no statistically signifi-
cant differences between the bespoke user-tested and
template-developed information sheets, so it may be
beneficial to develop a bank of template information
sheets rather than each trial having to take account of
the additional time and expense of professional user
testing. Alternatively, since many trials include PPI, a
more structured approach to reviewing and developing
the information sheet could be evaluated and then, if ef-
fective, adopted within PPI groups.
One reason why there may have been little evidence of a
difference is that the ‘standard’ PIS has been developed by
experienced researchers, and consequently it may be difficult
to achieve a significantly improved information sheet. It
could also be that the optimised PISs increased the interpre-
tably and clarity of the provided information, which deterred
some patients from responding. Unlike the other host trials
in the START programme, REFORM used a cohort rando-
mised controlled trial design. Participants were recruited
first to the observational cohort, and then eligible partici-
pants were randomised to the REFORM trial. Therefore,
optimised PISs were more likely to have an effect on recruit-
ment to the observational cohort than randomisation into
the REFORM trial. As there was a lack of effect on recruit-
ment to the observational cohort, it was unlikely that there
would be an impact on recruitment or retention in the trial.
There are some potential limitations to this study.
First, the results of this study are applicable only to
those participants over the age of 65 years attending
routine podiatry clinics. Further studies should substan-
tiate the study results in other populations. Second, due
to the nature of the intervention, it was not possible to
blind administrative staff who mailed out the recruit-
ment packs, but it is unlikely that allocation subversion
could have taken place. Whilst participants were aware
of which PIS they received, they were unaware that an
embedded trial was being conducted and that recruit-
ment to the REFORM study was being monitored.
Finally, it was not possible to evaluate whether the
enhanced information sheets affected the speed of re-
cruitment, as podiatry clinics were limited to the num-
ber of participants they could see at any one time.Conclusions
Optimised participant information sheets are one of a
number of recruitment interventions amenable to testing
through embedded trial methodology. Whilst the results
of this study suggest limited benefits to enhancing pa-
tient information sheets, the findings add to the body of
evidence around the effectiveness of recruitment strat-
egies and may potentially help save time and money in
future trials. The results of this study and the other em-
bedded studies for the MRC START programme are to
be incorporated into a meta-analysis which will provide
more robust evidence as to the effectiveness of these
types of recruitment strategies.Guidelines for reporting embedded recruitment trials
The guidelines are obtained from the following source:
Vichithranie W. Madurasinghe and Sandra Eldridge on
behalf of the MRC START group and Gordon Forbes on
behalf of the START Expert Consensus group. Trials.
2016;17:27. Published online 2016 Jan 14. doi: 10.1186/
s13063-015-1126-y.Additional files
Additional file 1: Original, control patient information sheet. (DOC 103 kb)
Additional file 2: Bespoke user-tested patient information sheet.
(PDF 328 kb)
Additional file 3: Template-developed patient information sheet.
(PDF 162 kb)
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